SuppreMol
Development of new therapies for autoimmune diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
€200m (Public information from Mar 2015)
Company register number HRB 189428 B (Charlottenburg (Berlin))
Planegg Bavaria (HQ)
Financials
Estimates*
EUR | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
---|---|---|---|---|---|---|---|
Profit | (8.4m) | (4.7m) | (<1m) | <1m | <1m | (<1m) | (<1m) |
Date | Investors | Amount | Round |
---|---|---|---|
N/A | Spinout | ||
$5.2m | Series A | ||
€15.7m | Series B | ||
€15.5m | Series C | ||
€6.5m | Series D | ||
€9.5m | Series D | ||
€200m Valuation: €200m | Acquisition | ||
Total Funding | €51.9m |